Home › Research › Topics › pet
pet
1,161 studies tagged pet, dated 1983-08-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Large-scale head-to-head comparison of on- and off-target profiles of [18F]Tauvid and [18F]MK6240 tau-PET in aging and Alzheimer’s disease 2026-11-01
- Detection of tau spatial extent using MK6240 and flortaucipir PET 2026-10-28
- Soluble amyloid composition links proximal APP processing, fibrillar burden and the p-tau181 response 2026-10-22
Studies
1,161 studies carry this tag.
Date range
1983 to 2026
Top journals
- Neurology 88
- Alzheimer's & dementia : the journal of the Alzheimer's Association 57
- Brain : a journal of neurology 52
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine 51
- Alzheimer's research & therapy 34
337 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
[ 18 F]Tauvid and [ 18 F]MK6240 capture largely overlapping patterns of tau pathology, but differ notably in the magnitude of off-target binding.
-
TSE showed stronger unadjusted associations than SUVR in selected region- and outcome-specific comparisons, supporting its potential as a complementary measure.
-
Amyloid biomarkers sample distinct levels of an open, kinetically coupled biochemical system, yet scalar summaries may obscure biologically relevant configuration.
-
ADNI identified task-dependent performance boundaries, particularly attenuated conditional T discrimination within A+.
-
: Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia).
-
16/100
Tau-PET subtype modified the p-tau217–memory association, suggesting that the cognitive implications of plasma p-tau217 may vary with tau topography.
-
MTD showed excellent discrimination of CU versus MCI/DEM (AUC=.89; 95% CI=.87-.92), and discriminability remained high for CU versus MCI (AUC=.88; 95% CI=.85-.92).
-
Alzheimer's disease staging from structural magnetic resonance imaging (MRI) is challenging when clinically adjacent stages and severe class imbalance are considered simultaneously.
-
Thirty-three AD subjects, aged 69.3 ± 8.2 years (mean ± standard deviation), 18 females, and 22 HCs aged 70.5 ± 13.3 years, 15 females, were evaluated.
-
Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease.
-
37/100
Expert panels interpreted 1497 scans. Participants were a median age of 75 y (range, 65-96 y), 51.4% were female, and 60.5% had mild cognitive impairment.
-
BackgroundDementia is rising worldwide, and in Alzheimer Disease (AD) the loss of communication adds to the burden.
-
PVeD reproducibly contextualized associations between plasma pTau217 and PET-defined Alzheimer pathology across cohorts with different participant composition, pTau217 assays, PET tracers, and cognitive measures.
-
At a care setting-agnostic cutoff of 0.934 pg/ml, high negative predictive value (NPV) (93.8%) and acceptable positive predictive value (PPV) (46.6%) were observed against amyloid-positron emission tomography (PET).
-
Alzheimers disease (AD) is characterized by substantial clinical and biological heterogeneity, with diverse neuroanatomical, cognitive, clinical, functional, and genetic risk profiles that are poorly captured by current diagnostic frameworks.
-
41/100
Older adults with Alzheimer's disease (AD) frequently present to emergency departments (EDs) with multiple coexisting conditions.
-
Early identification of Alzheimers disease and related dementias (ADRD) remains challenging despite its importance for timely intervention, management of modifiable risk factors, and care planning.
-
Anti-amyloid monoclonal antibody therapies (AATs) are increasingly used for the treatment of early symptomatic Alzheimer disease.
-
46/100
Four cognitive phenotypes emerged. One phenotype (18% of Aβ+ participants) showed the steepest cognitive decline, highest progression on the CDR, greater baseline medial temporal tau, and fastest neocortical tau accumulation over 4.6 years (hazard ratio [HR] for decline ≈ 2.9).
-
BackgroundThe Centiloid (CL) scale standardizes global amyloid PET quantification and is widely used to define amyloid positivity.
-
Understanding how the contents of consciousness, particularly perceptual awareness, change with the progression of AD is crucial for meaningful person-centred care.
-
Neuropsychiatric symptoms (NPS) are increasingly recognized as critical components of the disease progression in Alzheimers disease (AD), yet their relationship with neurodegeneration remain poorly characterized.
-
BackgroundThe brain age gap (BAG), the difference between neuroimaging-predicted and chronological age, captures inter-individual variation in brain aging.
-
BACKGROUNDQuantitative amyloid-beta (A{beta})-PET is increasingly used in AD prevention trials.
-
Brain perfusion SPECT revealed AD-typical hypoperfusion patterns and demonstrated modest potential to estimate the presence or absence of Aβ deposition with left parietal rCBF.
-
Ninety-six non-artifactual Amyloid-Tau components were identified, of which 73 showed appreciable spatial correspondence between their paired Amyloid and Tau maps, while 17 were Tau-localized and 6 Amyloid-localized.
-
Combining plasma p-tau with Aβ42 or the Aβ42/40 ratio reduced the intermediate zone.
-
41/100
A total of 51 patients with AD, age (median: 73 years) and 53 cognitively normal subjects (median age: 69) were included.
-
This study investigated whether WM measures derived from amyloid-PET are associated with AD biomarkers and to determine whether they offer added diagnostic and prognostic value beyond established biomarkers.
-
Effect size analysis proves the fact that the hybrid model produces statistically significant performance, as well as cases of clinically meaningful improvements over lightweight CNN baselines.
-
Alzheimer's disease progresses heterogeneously across diverse cohorts, yet current predictive models fail to capture this complexity while remaining clinically interpretable.
-
Early and accurate prognosis of Alzheimer’s disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline.
-
Accurate estimation of Alzheimer's disease (AD) severity from structural magnetic resonance imaging (MRI) remains difficult, as disease-associated anatomical alterations are often subtle and publicly available datasets are typically too small to support robust deep learning model training.
-
As the world's population ages, Alzheimer's disease (AD), a progressive neurodegenerative disorder, is becoming more common.
-
The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I2 = 95%).
-
This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired).
-
DPM is fundamentally constrained by dynamic range, variability, and test–retest reliability of the biomarker of interest.
-
Alzheimer's blood-based biomarker (BBM) tests using single biomarkers or ratios are well characterized, but head-to-head comparisons of multi-analyte algorithmic tests on shared cohorts are lacking.
-
Artificial intelligence (AI) has stimulated extensive research in clinical neurology, but relatively few AI systems have meaningfully changed bedside decision-making.
-
36/100
Blood-based biomarkers are increasingly used to triage patients for amyloid confirmation, yet performance is often reported versus a single comparator despite discordance between amyloid PET and CSF.
-
26/100
The accurate diagnosis tends to remain critical for the improvement of the patient outcomes in the Alzheimer’s disease (AD), where a progressive neurodegenerative disorder with the growing of the global impact.
-
Alzheimer Disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β deposition, tau pathology, synaptic dysfunction, neuronal injury and cerebral atrophy.
-
The Hierarchical-Circular Model of Biological Memory offers a unifying hypothesis for Alzheimer's disease and related dementias that bridges genetic, epigenetic, physiological, neuroimmune, and interoceptive processes across the lifespan.
-
Alzheimer disease (AD) destroys brain cells and the patient’s memory is lost as a result of a progressive and incurable neurodegenerative disease.
-
Enhanced connectivity between attention networks may be a characteristic of CR benefits in individuals with mild Alzheimer disease.
-
71/100
Plasma p-tau217 showed the strongest individual association with Aβ PET status (area under the curve [AUC], 0.85).
-
Dementia research often suffers from methodological pitfalls such as label-information and subject-information leakages.
-
Accurate and reproducible electroencephalography (EEG)-based classification of dementia remains a key challenge in computational neurodiagnostics.
-
We identified 8 brain structural features from 192 MRI features that were associated with the risk of MCI progressing to AD, including: left hippocampus, left inferior lateral ventricle, left amygdala, right middle temporal gyrus, left fusiform gyrus, right amygdala, left cortical total volume, and brain parenchyma total volume.
-
Comparing those having MCI, both CU and SCD participants had significantly lower amyloid PET standardized uptake value ratio (SUVR) (p < 0.001; p = 0.005).
From across this tag
9 of the 1,157 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population
- Integration of amyloid-β oligomerization tendency as a plasma biomarker in Alzheimer's disease diagnosis
- Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease
- EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects
- Optimized Neural Network Architectures for Early Detection of Alzheimer\'s disease Using MRI Images
- Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease
- Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale
- Multi-modal data analysis for early detection of alzheimer’s disease and related dementias
- Alzheimer's Disease Detection Through Whole-Brain 3D-CNN MRI